This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through September 7, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair Loss
by Zacks Equity Research
Eli Lilly's Olumiant wins FDA nod to treat pediatric patients 12 years of age and older with severe alopecia areata, expanding its U.S. use after strong phase III results.
LLYNegative Net Change INCYNegative Net Change ACIUNegative Net Change PGENPositive Net Change
biotechnology biotechs medical pharmaceuticals
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
by Ahan Chakraborty
RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.
ALNYNegative Net Change ARCTNegative Net Change IONSNegative Net Change WVENegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?
by Kinjel Shah
BIIB's growth products now outpace its legacy MS portfolio, with Skyclarys, Zurzuvae and newer drugs driving a shift in revenue mix.
BIIBNegative Net Change LLYNegative Net Change SUPNPositive Net Change ABBVPositive Net Change
biotechs
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal
by Zacks Equity Research
Acadia stock falls 13% after its Alzheimer's psychosis study narrowly misses its primary goal, though 60 mg results support continued phase III development.
ACADPositive Net Change ALDXNegative Net Change ACIUNegative Net Change PGENPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?
by Ekta Bagri
Bristol Myers Squibbs' growth portfolio is gaining ground, with newer drugs offsetting mature-product declines and reshaping its revenue mix.
BMYNegative Net Change PFENegative Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?
by Zacks Equity Research
Exelixis faces a three-month FDA review delay for zanzalintinib, pushing the potential CRC decision to March 2027.
EXELPositive Net Change RHHBYNegative Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
by Ahan Chakraborty
RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive funding through early 2028.
RXRXPositive Net Change SDGRNegative Net Change RLAYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?
by Kanishka Das
Precigen's Papzimeos is gaining commercial momentum, while its pipeline potential through the AdenoVerse platform could create new growth opportunities.
PGENPositive Net Change MRKPositive Net Change INONegative Net Change
biotechs
Beyond Imbruvica: Can AbbVie Rebuild Its Oncology Portfolio?
by Sundeep Ganoria
ABBV is expanding its oncology pipeline with newer therapies and diverse approaches to offset Imbruvica's decline.
ABBVPositive Net Change AZNNegative Net Change PFENegative Net Change MRKPositive Net Change
biotechs medical pharmaceuticals
ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data
by Zacks Equity Research
Oruka's ORKA-001 delivers deeper psoriasis clearance at week 28, but safety disclosures may have weighed on shares despite positive efficacy data.
ORKAPositive Net Change ALDXNegative Net Change ACIUNegative Net Change PGENPositive Net Change
biotechnology biotechs medical pharmaceuticals